19X Stock Overview
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Axsome Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$91.80 |
| 52 Week High | US$135.55 |
| 52 Week Low | US$59.56 |
| Beta | 0.88 |
| 1 Month Change | -20.21% |
| 3 Month Change | 1.62% |
| 1 Year Change | 48.78% |
| 3 Year Change | 156.28% |
| 5 Year Change | 31.73% |
| Change since IPO | 2,413.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 19X | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 8.0% | 2.0% | 4.1% |
| 1Y | 48.8% | -19.4% | 8.4% |
Return vs Industry: 19X exceeded the German Pharmaceuticals industry which returned -19.6% over the past year.
Return vs Market: 19X exceeded the German Market which returned 7.8% over the past year.
Price Volatility
| 19X volatility | |
|---|---|
| 19X Average Weekly Movement | 9.9% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 19X's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 19X's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 683 | Herriot Tabuteau | www.axsome.com |
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder.
Axsome Therapeutics, Inc. Fundamentals Summary
| 19X fundamental statistics | |
|---|---|
| Market cap | €4.47b |
| Earnings (TTM) | -€252.06m |
| Revenue (TTM) | €338.48m |
13.2x
P/S Ratio-17.7x
P/E RatioIs 19X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 19X income statement (TTM) | |
|---|---|
| Revenue | US$385.69m |
| Cost of Revenue | US$33.30m |
| Gross Profit | US$352.39m |
| Other Expenses | US$639.61m |
| Earnings | -US$287.22m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 05, 2025
| Earnings per share (EPS) | -5.89 |
| Gross Margin | 91.37% |
| Net Profit Margin | -74.47% |
| Debt/Equity Ratio | 317.0% |
How did 19X perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/19 10:52 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Axsome Therapeutics, Inc. is covered by 25 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Esther Lannie Hong | Berenberg |
| Jason Matthew Gerberry | BofA Global Research |